X0306 4 2016-09-16 0 0001466301 Clovis Oncology, Inc. CLVS 0001268304 IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY BOULDER CO 80301 0 1 0 0 See Remarks Stock Option (right to buy) 79.05 2016-09-16 4 J 0 8750 0.00 D 2025-03-02 Common Stock 8750 26250 D The Reporting Person voluntarily forfeited the option as to 8,750 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib. Following such forfeiture, the Reporting Person holds the option as to the remaining 26,250 shares (the "Remaining Shares"). The option vested as to 4,375 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 13,125 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 8,750 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib. Executive Vice President of Technical Operations and Chief Regulatory Officer /s/ Gillian C. Ivers-Read 2016-09-16